BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:45 PM
 | 
Feb 03, 2010
 |  BC Extra  |  Clinical News

Vertex reports VX-809 data

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said two doses of oral VX-809 once daily met the secondary efficacy endpoint of significantly reducing mean sweat chloride levels vs. placebo in a Phase IIa trial to treat cystic...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >